# Rasburicase in Tumor Lysis Syndrome

> **NCT00302653** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 33 (actual)

## Conditions studied

- Hyperuricemia

## Interventions

- **DRUG:** Rasburicase

## Key facts

- **NCT ID:** NCT00302653
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2006-11
- **Final completion:** —
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2009-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00302653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00302653, "Rasburicase in Tumor Lysis Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00302653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*